ArticleFrontiers in oncology2025
Case Report: Recurrent phyllodes tumor of the breast with progressive malignant transformation.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phyllodes Tumor of the Breast (PTB) is a rare fibroepithelial tumor often misdiagnosed as fibroadenoma, leading to delayed or incorrect treatment. Although most PTBs are benign, some cases exhibit recurrent growth and progression to malignant forms. This report presents a 52-year-old female patient with PTB, who experienced multiple recurrences since her initial surgery in 2012, with the pathological grade gradually progressing from benign to borderline and ultimately malignant, characterized by heterologous osteosarcomatous differentiation. The tumor showed high heterogeneity and rapid progression. The final diagnosis was malignant phyllodes tumor of the breast with focal osteosarcomatous stromal components. Immunohistochemistry revealed a significant increase in the Ki-67 index from 8% to 70%, MDM2 positivity, and abnormal p53 expression, suggesting molecular transformation mechanisms. The patient underwent a modified radical mastectomy and three cycles of postoperative systemic chemotherapy with a combination of ifosfamide and cisplatin, which was well-tolerated. Thirty-six months after surgery, there was no recurrence or metastasis, and the disease remained stable. This case highlights the progression of PTB from benign to malignant and suggests that elevated Ki-67 and abnormalities in MDM2/p53 could serve as potential molecular markers. For patients with multiple recurrences or heterogeneous PTB components, individualized treatment strategies are recommended, with reference to soft tissue sarcoma protocols to optimize prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.